目的 评价我院临床药师为慢性肾脏病患者提供药物重整服务的效果。方法 对2017年12月~2018年3月入住肾内科的符合纳入标准的慢性肾脏病(CKD)患者进行药物重整(MR),并采用欧洲药学监护网络基金会(PCNE)对药物相关问题(DRP)最新分类版本(V8.02)进行分析总结。结果 60例患者中共有48例(占80.00%)患者出现了59个DRP,其中50个是治疗效果方面(占84.75%);71个原因中医嘱方面的原因最多,有54个(占76.06%);造成的临床1级危害较多,有50个(占84.75%);临床药师共进行了145条干预,其中102条(占70.34%)干预被完全接受并执行。结论 CKD患者中DRP很常见,临床药师应对慢性肾脏病患者开展药物重整服务,并作为常规工作开展。
Abstract
OBJECTIVE To evaluate the efficacy of medication reconciliation (MR) service provided by clinical pharmacist for chronic kidney disease(CKD).METHODS Patients with CKD administered in department of nephrology between Dec, 2017 and Mar. Total of 2018 who met the inclusion criteria were given MR service, and the newest Pharmaceutical Care Network Europe (PCNE) V8.02 classification scheme was constructed for drug related problems (DRP) to analysis and summary.RESULTS MR was conducted 48 times (accounted for 80%) on 60 patients during the study period. Total of 59 medication DRP were identified. The most common DRP was treatment effectiveness (accounted for 84.75%), there were 54 causes (accounted for 76.06%) were prescribing in 71 causes, all the causes were classified as likely to cause level 1 harm (accounted for 84.75%), clinical pharmacists made 145 interventions, 102 (70.34%) of these were completely accepted and implement.CONCLUSION DRPs are common in CKD patients, clinical pharmacists should provide MR for CKD patients, and conducted as routine work.
关键词
药物重整 /
慢性肾脏病 /
干预 /
临床药师
{{custom_keyword}} /
Key words
medication reconciliation /
chronic kidney disease /
intervention /
clinical pharmacist
{{custom_keyword}} /
中图分类号：
R952
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Joint Commission on Accreditation of Healthcare Organizations, USA. Using medication reconciliation to prevent errors. Sentinel Event Alert, 2006,32(35):1-4.
[2] ZIMMERMAN K M, SALGADO T M, DIXON D L. Medication reconciliation vs medication review. JAMA, 2017,318(10):965-966.
[3] YAO H J, LI P, LIU X Z, et al. Pharmaceutical care practice for admission medication reconciliation in the internal medicine inpatient by clinical pharmacists. J China Pharm (中国药房), 2017, 28(32):4580-4584.
[4] WU L L, ZHANG X R, HOU J Q, et al. Practice of medication reconciliation among chronic renal insufficiency patients by clinical pharmacists . J China Pharm (中国药房), 2017, 28(14):2002-2005.
[5] CHEN M, ZHANG G W, DU M, et al. Medication reconciliation practice for cancer patients by clinical pharmacists. Eval Anal Drug-Use Hosp China(中国医院用药评价与分析), 2017, 17(7):989-990, 993.
[6] HO C P, JF L T. The reliability and validity of the Chinese version of the eight-item morisky medication adherence scale. Value Health, 2014,17(7):A730.
[7] Foundation, PCNE. PCNE Classification for drug related problemsV8.02. . . http://www.pcne.org/upload/files/230_PCNE_classification_V8-02.pdf.
[8] BAYLIFF C D,EINARSON T R. Physician assessment of pharmacists′ interventions--a method of estimating cost avoidance and determining quality assurance. Can J Hosp Pharm, 1990,43(4):167-171, 195.
[9] MUELLER S K, SPONSLER K C, KRIPALANI S, et al. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med, 2012,172(14):1057-1069.
[10] LIU Y, CUI X L, LIU L H. Brief analysis of medication reconciliation between domestic and foreign. Chin Pharm J(中国药学杂志), 2015, 50(24):2099-2112.
[11] ZHANG L,WANG F,WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet, 2012, 379(9818):815-822.
[12] CHEN C Y, SHENG X Y, LIANG Y, et al. Pharmacists′ participation in the management of chronic kidney disease: a systematic review. Chin Pharm J(中国药学杂志), 2015, 50(1):80-84.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家临床重点专科(临床药学)建设项目资助
{{custom_fund}}
PDF(3352 KB)
